Pharmaceutical Technology on MSN
FDA approves Acadia’s Daybue Stix for Rett syndrome
The US Food and Drug Administration (FDA) has granted approval for Acadia Pharmaceuticals’ Daybue Stix (trofinetide).
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Stockhead on MSN
Neurotech raising $4 million to drive NTI164 development
Neurotech International, a clinical-stage biopharmaceutical development company focused on paediatric neurological disorders, ...
After her daughter A'Laiya was injured at school, Latarsher Allen shares harrowing details and her ongoing fight for policy changes.
Daybue Stix, a strawberry-flavored trofinetide powder mixable with water-based liquids, gains FDA approval for Rett syndrome treatment.
Neuren Pharmaceuticals shares in focus after US FDA approval of new DAYBUE STIX formulation, unlocking royalties and ...
In morning trade, the ASX 200 stock is up 3.5% to $19.59. Investors have been bidding the pharmaceuticals company's shares ...
A mum has been found guilty today of trying to kill her severely disabled daughter by stabbing her 16 times. Jurors at ...
For Americans living with rare diseases, the Rare Pediatric Disease Priority Review Voucher Program is a vital tool. Yet its reauthorization is at risk.
Capital Brief on MSN
FDA approves oral solution for Neuren's Rett syndrome treatment
Biopharmaceutical company Neuren Pharmaceuticals has announced that its US distributor, Acadia Pharmaceuticals, has received ...
The chemical synthesis peptide drugs market size was valued at USD 2.57 billion in 2024 and is predicted to hit around USD ...
Acadia Pharma's trofinetide has hit its efficacy targets in a phase 3 trial involving girls with the devastating neurological disorder Rett syndrome, although safety has dampened enthusiasm a little.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback